Preparation method of small nucleic acid medicine based on imitated micro RNA heterozygote
By designing Mock-miR single-stranded oligonucleotide fragments and forming double-stranded hybrids, the specificity and scope limitation of single-target small nucleic acid drugs are solved, and the multi-target therapeutic effect is improved and the toxic side effects are reduced. It is significantly better than traditional miRNA and siRNA efficacy.
Patent Information
- Application Number
- CN202411094331.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-09
- Publication Date
- 2024-12-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Due to the lack of target specificity and limited application scope, existing single-target small nucleic acid drugs are difficult to effectively treat multi-factorial and multi-mechanical diseases, and often produce off-target effects, resulting in poor efficacy.
Using a small nucleic acid drug preparation method based on imitating microRNA hybrids, the Mock-miR single-stranded oligonucleotide fragment was designed by selecting two key pathogenic genes, and the base adjustment was used to anneale to form a double-stranded hybrid. , used to specifically inhibit pathogenic gene expression.
Achieved the multi-target technology of "one drug and multiple targets", which significantly enhanced the therapeutic effect, reduced toxic side effects, and was able to target multiple pathogenic signal paths, significantly better than the efficacy of miRNA or siRNA alone, and expanded the scope of application .
Smart Images

Figure BDA0004987422730000061 
Figure BDA0004987422730000081
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to a method for preparing a small nucleic acid drug based on emulating a microRNA hybrid. Background Art
[0002] Small nucleic acid drugs have become a hot strategy and direction for the development of new drugs today. At present, small nucleic acid technologies used to inhibit gene expression mainly include the following four categories: natural microRNA (microRNA or miRNA), artificially designed small interfering RNA (small interference RNA or siRNA), artificially designed pseudo-microRNA (miRNA-MIMIC) and antisense nucleotides. Since their length is about 16-26 nucleotides, they are called small nucleotides; the first three exist in the form of micro double strands, while the latter exists in the form of single strands. These small nucleic acid technologies each have their own advantages and disadvantages: natural miRNA exists in almost all biological species cells, and they bind to target genes, that is, protein-coding messenger RNA (messenger RNA) siRNA works by partial base pairing with the 3' untranslated region sequence of target mRNA or mRNA. Therefore, each miRNA can inhibit multiple (several or even hundreds) target mRNAs at the same time. It belongs to the "one-to-many" mode of action and has the multi-target pharmacological characteristics of "one drug, multiple targets". However, its targets do not have the identity and specificity of physiological functions and pathological processes, and lack gene or target specificity. Its main function is to fine-tune mRNA levels after transcription to regulate and maintain the fine balance of multi-gene expression in cells. The mechanism of action of siRNA is different from that of miRNA. They are double-stranded small RNAs designed according to the specific sequence of the coding region of the target mRNA. In animal cells, There is no natural siRNA, so it is a non-natural exogenous molecule. They play a role in selectively inhibiting target genes by completely base pairing with the coding specific region sequence of the target mRNA. Although they are theoretically a "one-to-one" mode of action, they often produce off-target effects and inhibit non-target mRNAs, resulting in toxic side effects. siRNA is a traditional single-target pharmacological technology; miR-MIMIC technology is an artificially designed non-natural small RNA technology invented and patented by the inventor of this patent 17 years ago to change cell functions and disease processes by regulating gene expression (patent application number: 200710072003.6; CN101054580A), miR-MIMIC is a double-stranded small RNA designed according to the specific sequence of the 3' terminal non-coding region of the target mRNA, so it has target gene specificity and belongs to the "one-to-one" mechanism of action, so it also belongs to the category of traditional pharmacology of single target. Similar to natural miRNA, miR-MIMIC acts on the 3' terminal non-coding region of the target mRNA and exerts gene inhibition through the mechanism of partial base pairing. It can be seen that miR-MIMIC is a small RNA interference technology that is generally between miRNA and siRNA. Although it has been widely used in basic research and drug development, it belongs to the "single target" gene interference technology, which is similar to small interfering RNA (siRNA), which specifically knocks down the target gene transcript, that is, the mRNA encoding the protein. Although the miR-MIMIC technology and the exogenously introduced natural miRNA are similar in mechanism of action, both induce gene expression by incomplete pairing with the target mRNA sequence. Knockdown effect, but the former is a simulated miRNA artificially designed for a specific region in the full sequence of the target mRNA, which has absolute specificity for the target gene, while the latter is an exogenous miRNA designed based on the natural miRNA sequence, which can act on multiple mRNAs and does not have absolute specificity for the target gene. Although the small nucleic acid molecules designed using the miR-MIMIC technology principle have the specificity of the target mRNA, their "single target" nature limits their application range and the effect is difficult to achieve the best. This is because almost all human diseases belong to the multi-factor and multi-mechanism etiology and pathological development process. Interfering with only one factor or factor often does not achieve the expected drug effect due to the compensation effect from other redundant factors. On the other hand, natural miRNA lacks target specificity and its effect often depends on the cell background, and off-target effects often occur. This situation has greatly limited the application of miR-MIMIC as a small nucleic acid drug. .
[0003] So far, there are no reports on strategies or technologies that can address the shortcomings of this “single-target” small nucleic acid drug. Summary of the invention
[0004] To overcome the shortcomings of single-target small nucleic acid drugs.
[0005] The technical solution of the present invention is: a method for preparing a small nucleic acid drug based on emulating a microRNA hybrid, comprising the following steps:
[0006] Step 1: Select a specific disease target and two key targets, i.e. key pathogenic genes, based on the pathological mechanism of the target disease;
[0007] Step 2: According to the mRNA sequences of two key pathogenic genes, a Mock-miR single-stranded oligonucleotide fragment is designed respectively to obtain two Mock-miR single-stranded oligonucleotide fragments;
[0008] Step 3: According to the sequence characteristics of the two Mock-miR single-stranded oligonucleotide fragments, base adjustment is performed;
[0009] Step 4: synthesize two Mock-miR single-stranded oligonucleotide fragments, and anneal the two synthesized Mock-miR single-stranded oligonucleotide fragments together at low temperature for hybridization, so as to hybridize them into a double-stranded hybrid, that is, a small nucleic acid drug.
[0010] Preferably, the two key pathogenic genes are myocardial injury-causing genes or oncogenes.
[0011] Preferably, oncogenes include human delta-like protein 1 homolog (DLK-1) and neurotrophic tyrosine receptor kinase (NTRK). DLK-1 is enriched in tumor stem cells and is a marker of tumor stem cells. It is expressed at extremely low levels in normal cells, tissues and organs after human development is completed, but is highly expressed in tumors. Inhibition of DLK-1 can block tumor cell proliferation and metastasis. DLK-1 can also be used to develop molecular targets for the treatment of obesity and diabetes. NTRK is called a "diamond" gene because it has been identified as an oncogenic driver gene for adult and pediatric patients with pan-solid tumors. The marketed drugs and drugs under development targeting NTRK fusion mutations have significant clinical effects. Patients receiving treatment usually take effect quickly. Many advanced patients have been reborn after using NTRK inhibitors. It is as rare and precious as diamonds.
[0012] Preferably, the key pathogenic genes include carnitine palmitoyltransferase 1B-Cpt1b and mitochondrial ribosomal protein S5-Mrps5. The protein encoded by the Cpt1b gene is a member of the carnitine / choline acetyltransferase family, which is the rate-limiting enzyme in the β-oxidation pathway of long-chain fatty acids in muscle mitochondria and is required for the net transport of long-chain fatty acyl coenzyme a from the cytoplasm to the mitochondria. In the hearts of Cpt1b-deficient mice, myocardial cell regeneration and cardioprotection are stimulated and enhanced at the same time, thereby effectively reducing myocardial ischemia-reperfusion injury and subsequent scar formation. These research findings indicate that Cpt1b is a myocardial damaging factor, and knocking down this factor helps protect the heart and even treat certain heart diseases, especially those that require myocardial cell regeneration, such as myocardial infarction, myocardial ischemia-reperfusion, etc. injection injury, and heart failure. On the other hand, the mitochondrial ribosomal protein S5 encoded by the Mrps5 gene is associated with several diseases, including cardiomyopathy, familial hypertrophy, 15 and Raynaud-Cleese syndrome, and its related pathways include mitochondrial translation and protein metabolism. Experiments have found that the deletion of a single allele of Mrps5 in mice leads to increased cardiomyocyte proliferation and cardiac regeneration, and improves cardiac function in myocardial infarction. In addition, MRPS5 inhibition (doxycycline) can also effectively increase the proliferation of human induced pluripotent stem cell-derived cardiomyocytes. It can be seen that MRPS5 is also a myocardial injury factor, and knocking down this factor helps protect cardiac function in myocardial infarction.
[0013] Preferably, the disease targets include, but are not limited to, myocardial infarction, myocardial infarction reperfusion injury, lung adenocarcinoma, colorectal cancer, diabetes and obesity.
[0014] Preferably, the two Mock-miR single-stranded oligonucleotide fragments are each a 16-30 nucleotide (nt) long Mock-miR single-stranded oligonucleotide fragment, so as to specifically bind to the specific region of the pathogenic gene, thereby inhibiting the expression and function of the two pathogenic genes.
[0015] Preferably, after base adjustment, the two Mock-miR single-stranded oligonucleotide fragments have a potential base pairing ability of no less than 65%.
[0016] Preferably, the annealing temperature is 45°C to 50°C.
[0017] Beneficial effects of the present invention:
[0018] 1. For the first time, Mock-miR was organically combined to obtain a dual Mock-miR hybrid technology for designing small nucleic acid therapeutic drugs. The present invention is not only a simple upgraded version of miRNA, miR-MIMIC and siRNA technology, but also integrates the advantages of the three technologies, giving a single drug the function of eliminating the functions of dual key pathogenic genes and more effective treatment of diseases. It is a multi-target technology with one drug and multiple targets, which gets rid of the limitations of miRNA, miR-MIMIC technology and siRNA technology, expands the applicability, and most importantly enhances the therapeutic effect of drugs and reduces potential toxic side effects. This innovative The hybrid has the characteristics of multi-target pharmacology. The two different oligonucleotide fragments each target different pathogenic genes, which provides a new design idea for the preparation of nucleic acid drugs. Small nucleic acid drugs can target the expression and function of genes in two different cascades of the same pathogenic signal pathway, and can also target the expression and function of key genes in two different pathogenic signal pathways. It combines the inhibitory effects of two Mock-miRs on two different target genes into one, and has the multi-target pharmacological characteristics and action principle of one drug with multiple targets, making it a new technology. The key is that this hybrid drug that kills two birds with one stone is significantly better than their respective effects alone and the efficacy of the combination of the two.
[0019] 2. Mock-miR hybrid technology is not a single drug, but a strategy and technology. By using the principles, methods and steps of this technology, it is theoretically possible to design and prepare countless hybrid small nucleic acid drugs for various diseases and develop them into clinical drugs, which has great application potential. DETAILED DESCRIPTION
[0020] The present invention will be further described below in conjunction with the embodiments.
[0021] Example 1
[0022] The present invention provides an embodiment: a method for preparing a small nucleic acid drug based on emulating a microRNA hybrid, comprising the following steps:
[0023] Step 1: Select a specific disease target, in this case acute myocardial infarction;
[0024] Step 2: Select two key targets, i.e. two pathogenic genes, based on the pathological mechanism of the target disease: Cpt1b and Mrps5 in this case;
[0025] Step 3: According to the mRNA sequences of the two selected pathogenic genes, a 21-nt-long Mock-miR single-stranded oligonucleotide fragment is designed respectively. These oligonucleotide fragments can specifically bind to the corresponding target gene mRNA sequences, thereby inhibiting their expression and function. In this example, Mock-miR-Cpt1b: 5`-UAUCUCAGAGCGCUGGUCACU-3`, recorded as SEQ ID NO.1; Mock-miR-Mrps5: 5'-AAUAAACAGCGCUCUAGGGUC-3', recorded as SEQ ID NO.2; the negative control sequence is: 5'-AGGGTGCCCGTATCGTGAAAT-3', recorded as SEQ ID NO.3;
[0026] Step 4: Anneal the two oligonucleotide fragments at 50°C to form a double-stranded structure Mock-miR-Cpt1b×Mock-miR-Mrps5 hybrid:
[0027]
[0028] Denoted as SEQ ID NO.4.
[0029] This case verified the therapeutic effect of this hybrid and the feasibility and effectiveness of the pseudo-microRNA and AMO hybrid technology at the myocardial cell level and in the mouse myocardial infarction model. The experimental results of the obtained Mock-miR-Cpt1b×Mock-miR-Mrps5 hybrid in the myocardial ischemic cell model and the myocardial infarction mouse model are as follows:
[0030] The cultured human AC16 cardiomyocyte cell line and mouse primary cardiomyocytes were transfected with the previously synthesized hybrid or its corresponding negative control (NC) sequence: miR-NC. The levels of Cpt1b and Mrps5 mRNA and their corresponding proteins in cardiomyocytes were detected by qRT-PCR, Western Blot and FISH. It was found that 12 hours after transfection, the levels of Meox1 mRNA and MEOX1 protein decreased significantly, especially the protein level decreased by 78.4%. At the same time, ATP2A2 / SERCA2a levels were upregulated by 7.9 times and 4.1 times, respectively, after 24 hours.
[0031] An acute myocardial infarction model was established in C57BL / 6 mice. After tail vein injection of the lipid nanoparticle-encapsulated hybrid, it was found that compared with miR-NC and saR-NC, the hybrid significantly improved the following index changes:
[0032] (a) Echocardiography was used to measure parameters such as fractional shortening (FS), ejection fraction (EF), left ventricular end-diastolic diameter (LVIDd), and left ventricular end-systolic diameter (LVIDs) to evaluate cardiac function;
[0033] (b) The TTC staining method detected that the infarct area of the mouse heart was greatly reduced; the ELISA method detected that the LDH level in the mouse serum was significantly reduced;
[0034] (c) The Masson tricolor assay kit detected a significant decrease in the area of myocardial fibrosis, indicating that inhibiting MEOX1 expression effectively curbed the activation and proliferation of myocardial fibroblasts, thereby reducing the excessive production and deposition of collagen;
[0035] (d) Acutely isolated cardiomyocytes were used to detect that the contractile ability of cardiomyocytes was greatly improved, the intracellular calcium level decreased significantly and returned to normal, the instantaneous amplitude of intracellular calcium rebounded, and the rate of decline phase accelerated, indicating that the activation of ATP2A2 transcriptional expression greatly improved the intracellular calcium homeostasis;
[0036] (e) Using TUNEL kit to detect cardiomyocyte apoptosis, it was found that the hybrid effectively prevented and inhibited cell apoptosis;
[0037] (f) Electron microscopy showed that the hybrid treatment effectively protected the integrity of mitochondrial morphology and mitochondrial membrane.
[0038] It is worth emphasizing that the present invention conducted a drug efficacy comparison experiment in a mouse acute myocardial infarction model and found that at the same concentration, the miR-Meox1×AMO-142 / ATP2A2 hybrid had an effect of reducing myocardial infarction area and restoring EF of up to 79% and 81%, respectively, while the combined use of miR-Meox1 and saR-ATP2A2 reached 59% and 63%, miR-Meox1 reached 18%, and AMO-142 / ATP2A2 reached 39%. It can be seen that the efficacy of the hybrid is much greater than the individual effects of miR-Meox1 and AMO-142 / ATP2A2 and the sum of their effects, and is also much higher than the efficacy of the combined use of the two, indicating that the two complementary chains representing two different "drugs" in the miR-Meox1×AMO-142 / ATP2A2 hybrid have a positive synergistic effect.
[0039] Example 2
[0040] On the basis of Example 1, this example designed a nucleic acid drug for treating cancer: Mock-miR-DLK-1×Mock-miR-NTRK1 hybrid according to the operating steps of Example 1 and based on the principle of double Mock-miR hybrid technology, including the following process:
[0041] Two Mock-miR technology experimental verification sequences:
[0042] 5'-AACAGAAUCGUAGGCAUGCUC-3', recorded as SEQ ID NO.6, Mock-miR-DLK-1;
[0043] 5'-GAUAAUUGCUACGACUCGACC-3', recorded as SEQ ID NO.7, Mock-miR-NTRK1;
[0044] 5'-GAACTCGGTACGTATCTCTAA-3', recorded as SEQ ID NO.8, Mock-miR-NC (negative control);
[0045]
[0046] Note as SEQ ID NO. 9, Mock-miR-DLK-1×Mock-miR-NTRK1 hybrid;
[0047] DLK-1 is a transmembrane protein containing six epidermal growth factor repeat sequences. Its encoding gene belongs to a type of human imprinted gene. It is enriched in tumor stem cells and is a marker of tumor stem cells and tumor cells. It is expressed at very low levels in normal cells, tissues and organs after human development, but highly expressed in tumors, stimulating the stemness and growth of cancer cells. DLK1 can maintain the invasive stem cell characteristics of tumor cells, especially for central nervous system tumors, neuroblastoma and hepatocellular carcinoma. Overexpression of DLK1 is closely related to increased invasiveness and poor prognosis of glioblastoma, pancreatic cancer, hepatocellular carcinoma, ovarian cancer, prostate cancer and lung cancer. In contrast, inhibition of DLK-1 can block tumor cell proliferation and metastasis. In particular, increasing evidence shows that tumor cell resistance and recurrence are mainly due to the stem phenotype of tumor cells or the activity of tumor stem cells. Since DLK1 plays an important role in maintaining the stemness of tumor cells, inhibition of DLK1 can also reduce the resistance of tumor cells to therapeutic drugs.
[0048] NTRK1 is a member of the neurotrophic tyrosine kinase receptor family that encodes a high-affinity nerve growth factor and was originally identified as an oncogene in human colon cancer.
[0049] Experimental results of miR-Kras×AMO-let7 / TP53 hybrids at the cancer cell level and in nude mouse grafted tumor models:
[0050] In SK-BR-3 human breast cancer cell line and human AsPC-1 pancreatic cancer cell line, time-effect experiments showed that after 12 hours of transfection with the hybrid, a significant decrease in Kras protein and mRNA expression was found, while p53 protein and mRNA levels were not induced until 48 hours after transfection with the hybrid and continued to increase at 72 hours. The hybrid showed a strong ability to inhibit cell proliferation and colony formation, induce cell G0 / G1 arrest, and inhibit migration and invasion. Compared with the Mock group, miR-NC (negative control group for miR-Kras), and AMO-NC (negative control group for AMO-let7 / TP53) control treatments, transfection with the hybrid resulted in a significant increase in the G1 / G0 and G2 / M populations, while the S population decreased.
[0051] Treatment with the hybrid inhibited the proliferation of SK-BR-3 and AsPC-1 cells and induced apoptosis.
[0052] The hybrids inhibited the migration and invasion of SK-BR-3 and AsPC-1 cells. In addition, the hybrids could significantly inhibit the growth and metastasis of cancer nude mice tumors.
[0053] Most importantly, the present invention conducted a comparative experiment on the efficacy of nude mice grafted with breast cancer and pancreatic cancer tumors, and found that at the same concentration, the anti-cancer efficiency of the miR-Kras×AMO-let7 / TP53 hybrid reached 82%, the combined use of miR-Kras and saR-TP53 reached 67%, miR-Kras reached 35%, and AMO-let7 / TP53 reached 25%. It can be seen that the efficacy of the hybrid is far greater than the effects of miR-Kras and AMO-let7 / TP5 and the sum of the effects of the two, and is also much higher than the efficacy of the combined use of the two. This shows that the two fragments in the miR-Kras×AMO-let7 / TP53 hybrid have a positive synergistic effect.
[0054] In summary, the present invention provides a method for preparing a nucleic acid drug based on mimic microRNA and microRNA antisense oligonucleotides. The present invention organically combines mimic microRNA technology and AMO technology for the first time to obtain a mimic microRNA and microRNA antisense oligonucleotide hybrid technology for designing small nucleic acid therapeutic drugs. The present invention is not only a simple upgraded version of mimic microRNA technology and microRNA antisense technology, but also integrates the advantages of both, giving a single drug the function of eliminating pathogenic gene function and saving disease-resistant gene function and the effect of more effective disease treatment. It belongs to the multi-target technology of "one drug with multiple targets", gets rid of the limitations of mimic microRNA technology and microRNA antisense technology, expands the applicability, and most importantly, enhances the drug treatment effect and reduces potential toxic side effects. This innovative hybrid has the characteristics of multi-target pharmacology, in which the two different oligonucleotide fragments each have their own different functions: mimic microRNA is used to inhibit the expression of pathogenic genes; AMO is used to relieve the inhibition of miRNA on the expression of disease-resistant genes, thereby saving the suppressed target genes. From the perspective of mechanism of action, pseudo-microRNAs inhibit the expression of pathogenic genes at the post-transcriptional level by directly base pairing with the sequence of the target gene messenger RNA; AMOs relieve the inhibitory effect of the target microRNA on anti-disease genes by base pairing with the target sequence of the microRNA, providing a new design idea for the preparation of nucleic acid drugs.
[0055] Various embodiments of the present invention may be presented in the form of a range; it should be understood that the description in the form of a range is only for convenience and brevity, and should not be understood as a rigid limitation on the scope of the present invention; therefore, the range description should be considered to have specifically disclosed all possible sub-ranges and single numerical values within the range. For example, the range description from 1 to 6 should be considered to have specifically disclosed sub-ranges, such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc., as well as single numbers within the range, such as 1, 2, 3, 4, 5 and 6, which apply regardless of the range. In addition, whenever a numerical range is indicated herein, it is meant to include any cited number (fractional or integer) within the indicated range.
[0056] The embodiments of the present invention are described in detail above, but the present invention is not limited to the above embodiments, and various changes can be made within the knowledge scope of those skilled in the art without departing from the spirit of the present invention.
Claims
1. A method for preparing small nucleic acid drugs based on emulating microRNA hybrids; characterized in that: The steps include: Step 1: Select a specific disease target and two key targets, i.e. key pathogenic genes, based on the pathological mechanism of the target disease; Step 2: According to the mRNA sequences of two key pathogenic genes, a Mock-miR single-stranded oligonucleotide fragment is designed respectively to obtain two Mock-miR single-stranded oligonucleotide fragments; Step 3: According to the sequence characteristics of the two Mock-miR single-stranded oligonucleotide fragments, base adjustment is performed; Step 4: synthesize two Mock-miR single-stranded oligonucleotide fragments, and anneal the two synthesized Mock-miR single-stranded oligonucleotide fragments together at low temperature for hybridization, so as to hybridize them into a double-stranded hybrid, that is, a small nucleic acid drug.
2. The method for preparing a small nucleic acid drug based on emulating a microRNA hybrid according to claim 1, characterized in that: The two key pathogenic genes are either myocardial injury-causing or oncogenes.
3. The method for preparing a small nucleic acid drug based on emulating a microRNA hybrid according to claim 2, characterized in that: Oncogenes include human delta-like protein 1 homolog (DLK-1) and neurotrophic tyrosine receptor kinase (NTRK).
4. The method for preparing a small nucleic acid drug based on emulating a microRNA hybrid according to claim 1, characterized in that: The key pathogenic genes include carnitine palmitoyltransferase 1B-Cpt1b (Carnitine Palmitoyltransferase1B) and mitochondrial ribosomal protein S5-Mrps5 (Mitochondrial Ribosomal Protein S5).
5. The method for preparing a small nucleic acid drug based on emulating microRNA hybrids according to claim 1, characterized in that: Disease targets include, but are not limited to, myocardial infarction, myocardial infarction reperfusion injury, lung adenocarcinoma, colorectal cancer, diabetes, and obesity.
6. The method for preparing a small nucleic acid drug based on emulating a microRNA hybrid according to claim 1, characterized in that: Each of the two Mock-miR single-stranded oligonucleotide fragments is a Mock-miR single-stranded oligonucleotide fragment with a length of 16 to 30 nucleotides (nt).
7. The method for preparing a small nucleic acid drug based on emulating microRNA hybrids according to claim 1, characterized in that: After base adjustment, the two Mock-miR single-stranded oligonucleotide fragments have a potential base pairing ability of no less than 65%.
8. The method for preparing a small nucleic acid drug based on emulating a microRNA hybrid according to claim 1, characterized in that: The annealing temperature is 45°C to 50°C.
